Genomic Health: Bright Spot in a Tough Market

The following video is part of our "Motley Fool Conversations" series, in which senior analyst Matt Argersinger and analyst Paul Chi discuss topics across the investing world.

Not many stocks have been spared by the recent market downturn, but Genomic Health continues to trade close to its 52-week high, and for good reason. The small-cap company is a pioneer in the burgeoning field of molecular diagnostics, specifically for cancer screening, and demand for its state-of-the-art tests is growing by leaps and bounds. Genomic's Oncotype breast cancer test, launched in 2004, has become a leading alternative to the standard mammography. In 2010, Genomic launched a test for colon cancer and is in the process of developing tests for prostate and renal cell cancers. 

For Genomic Health, the market opportunity is huge. An estimated 1.6 million people in the United States and 12.7 million people worldwide were diagnosed with cancer in just the past year. Get Matt's full take on Genomic Health and why he sees it as a winning value proposition for both cancer patients and investors by watching the video below.

Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.

Matthew Argersinger has no positions in the stocks mentioned above. Paul Chi has no positions in the stocks mentioned above. The Motley Fool owns shares of Genomic Health and Laboratory Corp. of America. Motley Fool newsletter services recommend Genomic Health, Illumina, Laboratory Corp. of America, and Quest Diagnostics. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 27, 2012, at 3:52 PM, RxDan1 wrote:

    What we really need are recommendations for stock, bond or funds that will not be affected as much in January when potential, deep across-the-board tax cuts take place with the Feds committee designed for this purpose. Please write a nice article on this which can appear in the "Motley Fool Stock Advisor"


Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1924858, ~/Articles/ArticleHandler.aspx, 10/26/2016 9:42:55 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 26 minutes ago Sponsored by:
DOW 18,199.33 30.06 0.17%
S&P 500 2,139.43 -3.73 -0.17%
NASD 5,250.27 -33.13 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/26/2016 4:00 PM
GHDX $29.91 Down -0.04 -0.13%
Genomic Health CAPS Rating: ****
DGX $80.15 Down -3.02 -3.63%
Quest Diagnostics CAPS Rating: ****
ILMN $139.95 Up +1.77 +1.28%
Illumina CAPS Rating: *****
LH $126.46 Down -11.95 -8.63%
Laboratory Corpora… CAPS Rating: ****
LMNX $20.74 Down -0.54 -2.54%
Luminex CAPS Rating: ****